Hagens Berman Sobol Shapiro LLP on Mar. 31 reminds investors of the May 5, 2014, deadline to file for lead plaintiff in a securities fraud case against Galena Biopharma Inc (NASDAQ:GALE). The complaint filed in the U.S. District Court for the District of Oregon alleges that the company violated federal securities laws when it paid DreamTeam to write misleading articles under aliases without disclosing payment for the articles or any affiliation with the company. Galena Biopharma Inc (NASDAQ:GALE) shares after opening at $2.58 moved to $2.72 on last trade day and at the end of the day closed at $2.56. Company price to sales ratio in past twelve months was calculated as 120.71 and price to cash ratio as 6.31. Galena Biopharma Inc (NASDAQ:GALE) showed a negative weekly performance of -1.16%.
Idera Pharmaceuticals Inc (NASDAQ:IDRA) presented favorable top-line data from its mid-stage trial of IMO-8400 that is aimed at treating plaque psoriasis, from moderate-to-severe level of the ailment. As per the press release by the company, 32 patients were part of its phase 2 trial and that the drug provided successful data for both of its primary and secondary objectives, which was to evaluate the safety as well as tolerability of the drug on these patients. Additionally, the study was also aimed to capture the clinical activity of the drug. As per the study results, the therapy indicated tolerance without any treatment related discontinuation, critical material effect or reduction in dose. At the same time, its clinical activity was measured through Psoriasis Area and Severity Index (PASI), where the therapy achieved a score of 50, which implies a 50% improvement to baseline at week 12. The therapy returned the PASI score of 50 in nine out of 20 patients as against one out of seven in case of placebo.Idera Pharmaceuticals Inc (NASDAQ:IDRA) shares advanced 8.09% in last trading session and ended the day on $4.41. IDRA return on equity ratio is recorded as -444.00% and its return on assets is -114.30%. Idera Pharmaceuticals Inc (NASDAQ:IDRA) yearly performance is 748.08%.
Pacific Ethanol, Inc. (NASDAQ: PEIX) came within about 1% of hitting a new 52-week high on Tuesday. The operational update was provided in its 10-K commentary. Pacific Ethanol produced 149.7 million gallons of ethanol with sales of $908.4 million in 2013, versus $816.04 million in revenue and 140.6 million gallons in 2012. Pacific Ethanol Inc (NASDAQ:PEIX) shares moved up 14.89% in last trading session and was closed at $17.90, while trading in range of $15.11-$17.98. Pacific Ethanol Inc (NASDAQ:PEIX) year to date performance is 251.67%.
Shares of XOMA Corp (NASDAQ:XOMA) have received an average rating of “Hold” from the ten analysts that are presently covering the company, American Banking News.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $9.00. XOMA Corp (NASDAQ:XOMA) weekly performance is %. On last trading day company shares ended up $5.27. XOMA Corp (NASDAQ:XOMA) distance from 50-day simple moving average is -26.46%. Analysts mean target price for the company is $9.33.